What is OTLK's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for OTLK.

Stock Ratings / Health Care / OTLK / options

HUMA (30) AVXL (32) ARMP (32) VYGR (15) ⌘ Pro Terminal →

Outlook Therapeutics Inc. (OTLK) Options Positioning, Max Pain & Unusual Sweeps

$0.47 -5.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.46

Outlook Therapeutics Inc. (OTLK) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $114.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OTLK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OTLK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Outlook Therapeutics Inc. (NASDAQ: OTLK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.47 (-5.15% 1D, market cap $114.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OTLK ranks #599 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OTLK compare to HUMA and AVXL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OTLK carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 4.0%, and ROIC of -35.0%. By comparison, HUMA (Humacyte Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $114.2M) and AVXL (Anavex Life Sciences Corp.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $110.3M). Among the 5-stock peer group, OTLK leads on earnings multiple (N/A) while OTLK leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OTLK?

▼

Per OTLK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001649989), Outlook Therapeutics Inc. generated $1.4M in revenue (-99.3% YoY), -$62.4M in net income, and -$51.8M in free cash flow against $18.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.46 (-1.12%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OTLK)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY OTLK SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 4% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.58-15.5% Next Q

Q2 (-2Q)

Grade D$0.49+4.1% Next Q

Q3 (-1Q)

Grade E$0.51-7.8% Next Q

Current

Grade D-$0.47-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OTLK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OTLK currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.60) and Max Pain ($0.49) forces dealer call-delta covering toward $2.67.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OTLK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OTLK Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (OTLK)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for OTLK.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OTLK)

✓Walkthrough of OTLK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OTLK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +80.77%⚡ TESTING RESISTANCE

2026-11-03O $0.50H $0.50L $0.47C $0.47VOL 4.79M

RES: $0.52SUP: $0.39SMA50: $0.60SMA200: $0.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OTLK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OTLK Butterfly Map → + Track OTLK →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -99.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OTLK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OTLK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OTLK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OTLK)

Health Care Rank #599 of 1015 ⚔️ HUMA vs OTLK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OTLK vs. HUMA, AVXL, ARMP, VYGR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Outlook Therapeutics Inc. (OTLK) ranks #599 by composite RQD confidence (35/100, grade D-) and #633 by equity capitalization ($114.0M). Within this direct 5-issuer industry benchmark cohort, OTLK leads on earnings valuation at N/A trailing P/E, while OTLK leads on capital efficiency and profitability with -35.0% ROIC and 4.0% gross margin. OTLK currently leads its immediate peer cohort in composite quantitative strength at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OTLK ACTIVE Outlook Therapeutics Inc.	D-	35/100	—	4.0%	-35.0%	-5.15%	$114.0M	Benchmark Subject
HUMA Humacyte Inc.	E	30/100	—	-30.0%	-35.0%	-12.47%	$114.2M	/huma-vs-otlk →
AVXL Anavex Life Sciences Corp.	E	32/100	—	—	-35.0%	-8.46%	$110.3M	/avxl-vs-otlk →
ARMP Armata Pharmaceuticals Inc.	E	32/100	—	—	-35.0%	+0.92%	$122.0M	/armp-vs-otlk →
VYGR Voyager Therapeutics Inc.	E	15/100	—	—	-35.0%	-2.27%	$106.0M	/vygr-vs-otlk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001649989 ↗

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Outlook Therapeutics Inc. (OTLK) reported GAAP revenue of $1.4M (-99.3% vs. FY2024 revenue of $200.8M , and -99.0% cumulative change since FY2023) , GAAP net income of -$62.4M, operating cash flow of -$51.8M, and free cash flow of -$51.8M (+24.7% YoY). On the balance sheet, OTLK closed FY2025 with $18.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$1.4M	-$62.4M	-$51.8M	-$51.8M	$18.2M	—
FY2024 (FY)	2024-09-30	$200.8M	-$75.4M	-$68.8M	-$68.8M	$17.0M	—
FY2023 (FY)	2023-09-30	$148.8M	-$59.0M	-$43.0M	-$43.0M	—	—

3. OTLK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OTLK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does OTLK compare to HUMA and AVXL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for OTLK?

Where is OTLK trading relative to its 50-day, 200-day, and 52-week technical levels?

OTLK last traded at $0.47 (-5.15% on volume of 4,794,550 shares), positioning the stock -21.67% below its 50-day simple moving average ($0.60) and -28.79% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.16 to $2.54, OTLK sits at the 13.0% percentile with a 14-day RSI of 37.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.53).

Direct Sub-Reports: OTLK RQD Cockpit OTLK 12M Forecast OTLK Earnings & Move OTLK Dividends & DRIP OTLK Insiders & 13F OTLK Whale Options OTLK Profit Sankey OTLK News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

OTLK — Outlook Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Outlook Therapeutics Inc. (OTLK) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.47 (-5.15% 1D, market capitalization $114.0M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 4.0%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Outlook Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Its market capitalization is $0.1B. FY 2025 revenue was $1.4M against FY 2024 and FY 2023 revenue of —.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Outlook Therapeutics Inc. (OTLK) reported $1.4M in annual revenue (up from $200.8M in FY2024, -99.3% YoY) and -$62.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($148.8M revenue, -$59.0M net income) through FY2025, OTLK scaled operating cash flow to -$51.8M and free cash flow to -$51.8M, backed by $18.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.16 – $2.54 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), OTLK carries a macro regime beta of 1.00 and gross margin of 4.0%.

Key Question #1: Can OTLK sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.4M and free cash flow of -$51.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is OTLK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OTLK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Outlook Therapeutics Inc. (OTLK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OTLK Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Yahoo Finance report covering Outlook Therapeutics Inc. (OTLK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Two reported owners share voting power over a stake above 5% in Outlook Therapeutics (OTLK).

Stock Titan report covering Outlook Therapeutics Inc. (OTLK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Outlook Therapeutics, Inc. Estimates – NASDAQ:OTLK

TradingView report covering Outlook Therapeutics Inc. (OTLK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026.

www.marketscreener.com report covering Outlook Therapeutics Inc. (OTLK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Outlook Therapeutics Highlights What the Appointment of New

GlobeNewswire report covering Outlook Therapeutics Inc. (OTLK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Outlook Therapeutics Inc (OTLK) Stock Price Target & Forecast

TradingKey report covering Outlook Therapeutics Inc. (OTLK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Outlook Therapeutics, Inc. (OTLK) Seasonal returns chart

Yahoo Finance UK report covering Outlook Therapeutics Inc. (OTLK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OTLK Bull vs. Bear Conversation Board — What's Your Call at $0.47?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OTLK 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $0.55 (+17.0%)

📌 Pinned Debate

Institutional accumulation and options positioning earn the highest pillar score at 11/20, the main offset to weak fundamentals.

Picked up a starter position in OTLK in my $100K Virtual Cash book at $0.47. Institutional accumulation and options positioning earn the highest pillar score at 11/20, the main offset to weak fundamentals.. Trading inside a $0.16–$2.54 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

CapAlloc_Nerd 🐂 BULL

@QuantViper Agree on the RQD 35/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.47 and keeping dry powder in case we test $0.44.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.36 (-23.4%)

Spot @ $0.47

Negative ROIC of -35%, a 0% FCF yield, and a Piotroski F-Score of 2/9 leave the balance sheet and cash generation vulnerable.

Negative ROIC of -35%, a 0% FCF yield, and a Piotroski F-Score of 2/9 leave the balance sheet and cash generation vulnerable.. Look at the math on OTLK: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $0.41 before getting long.